Table 1.
The pretreatment clinical characteristics of the subjects in the WMCGs and the 0.1% SH groups
| WMCG group (N = 22) | 0.1% SH group (N = 18) | ||
|---|---|---|---|
| Median (25%,75%)/ | Median (25%,75%)/ | P | |
| Mean ± SD | Mean ± SD | ||
| Age (Year) | 26.5 (25, 28.25) | 26 (25, 27.25) | 0.510 |
| Gender (M:F) | 8:14 | 6:12 | 0.968 |
| VDT (h) | 9.41 ± 1.87 | 9.79 ± 2.01 | 0.570 |
| FBUT (s) | 3.49 ± 0.97 | 3.52 ± 1.22 | 0.665 |
| ABUT (s) | 4.86 ± 1.34 | 4.92 ± 1.69 | 0.936 |
| CFS | 1 (0,3.25) | 0 (0,2) | 0.244 |
| SIt (mm) | 16.49 ± 10.98 | 15.63 ± 11.69 | 0.824 |
| IOP (mmHg) | 14.51 ± 2.38 | 15.00 ± 2.18 | 0.434 |
| OSDI | 37.49 ± 15.24 | 36.93 ± 16.69 | 0.918 |
WMCGs warming moist chamber goggles, SH sodium hyaluronate, VDT video display terminals, FBUT first break-up time, ABUT average break-up time, CFS corneal fluorescein staining, SIt Shirmer I test, IOP intraocular pressure, OSDI ocular surface disease index